Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Approval Safety Monitoring Program to Assess the Safety and Efficacy Profile of TUKYSA in Usual Practice

NCT06873191 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06873191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06873191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Approval Safety Monitoring Program to Assess the Safety and Efficacy Profile of TUKYSA in Usual Practice
Lead sponsor
Pfizer
Phase
Observational
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
May 1, 2029
Enrollment
600 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive locally advanced unresectable, metastatic breast cancer